Cargando…

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

INTRODUCTION: The prognostic significance of p53 protein expression in early breast cancer remains uncertain, with some but not all studies finding an association with poorer outcomes. Estrogen receptor (ER) expression is both a positive prognostic marker and predictive of response to endocrine ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coates, Alan S, Millar, Ewan KA, O'Toole, Sandra A, Molloy, Timothy J, Viale, Giuseppe, Goldhirsch, Aron, Regan, Meredith M, Gelber, Richard D, Sun, Zhuoxin, Castiglione-Gertsch, Monica, Gusterson, Barry, Musgrove, Elizabeth A, Sutherland, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053129/ https://www.ncbi.nlm.nih.gov/pubmed/23127292 http://dx.doi.org/10.1186/bcr3348

Ejemplares similares

Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
por: Varga, Zsuzsanna, et al.
Publicado: (2019)

Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).
por: Bernhard, J., et al.
Publicado: (1998)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Lacerations to Zones VIII and IX: It Is Not Just a Tendon Injury
por: Fischer, Charla R., et al.
Publicado: (2011)

Further Data on the Stanford-Binet VIII- and IX-Year Tests
por: Wallin, J. E. Wallace
Publicado: (1933)

Augmented Degradation of Factors VIII and IX in the Intermittent Movement State
por: Cohen, Haim, et al.
Publicado: (2023)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
por: Pagani, Olivia, et al.
Publicado: (2020)

Discharged. Not Where to Lay His Head: Chapters VII, VIII, IX
por: Fleming, George
Publicado: (1886)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
por: Johansson, Harriet, et al.
Publicado: (2016)

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
por: Bernhard, J, et al.
Publicado: (2008)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX
por: Yoo, Ki-Young, et al.
Publicado: (2018)

The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX
por: Wilmot, Helen V., et al.
Publicado: (2020)

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
por: Bernhard, J, et al.
Publicado: (2004)

Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report
por: Doma, Saša Anžej, et al.
Publicado: (2016)

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence
por: Conforti, Fabio, et al.
Publicado: (2019)

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
por: Goldhirsch, A., et al.
Publicado: (2011)

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
por: Goldhirsch, A., et al.
Publicado: (2009)

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
por: Colleoni, M, et al.
Publicado: (2002)

Maturation of coagulation factor IX during Xase formation as deduced using factor VIII‐derived peptides
por: Fang, Han, et al.
Publicado: (2019)

Effects of preanalytical frozen storage time and temperature on screening coagulation tests and factors VIII and IX activity
por: Zhao, Ying, et al.
Publicado: (2017)

凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南（2018年版）
Publicado: (2018)

PB2655: EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR
por: Koyun, Derya, et al.
Publicado: (2023)

Cloning and expression of two new prolactin-related proteins, prolactin-related protein-VIII and -IX, in bovine placenta
por: Ushizawa, Koichi, et al.
Publicado: (2005)

Notes, with Observations, on Cases Treated in the Surgical Wards VIII., IX., X., XI., and XII., Royal Infirmary, Edinburgh
por: Bennett, Alexander
Publicado: (1871)

Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review
por: Bosch, Alessandra, et al.
Publicado: (2023)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Molecular Analysis of Factor VIII and Factor IX Genes in Hemophilia Patients: Identification of Novel Mutations and Molecular Dynamics Studies
por: Al-Allaf, Faisal A., et al.
Publicado: (2017)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

International Web-based consultation on priorities for translational breast cancer research
por: Dowsett, Mitch, et al.
Publicado: (2007)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
por: Coates, A. S., et al.
Publicado: (2015)

The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience
por: Bouyadmar, Meryem, et al.
Publicado: (2022)

Extra-Abdominal Desmoid Tumours: A Review of the Literature
por: Molloy, A. P., et al.
Publicado: (2012)

BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
por: Millar, E K A, et al.
Publicado: (2009)

Cases and Observations in Medical Jurisprudence.—VIII. Trial for Poisoning with Sulphuric Acid.—IX. Two Trials Involving the Question of Burning before or after Death
por: Christison, Robert
Publicado: (1831)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_53rhukqupan2idofs4hbgc48u4